{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:05:02Z","timestamp":1791295502525,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,2,13]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>JAK2R564Q is the first germline JAK2 mutation found to contribute to a familial MPN that involves a residue other than V617. The kinase activity of JAK2R564Q and JAK2V617F are the same, but only V617F is able to escape regulation by SOCS3 and p27.<\/jats:p>","DOI":"10.1182\/blood-2012-12-473777","type":"journal-article","created":{"date-parts":[[2013,12,31]],"date-time":"2013-12-31T21:53:20Z","timestamp":1388526800000},"page":"1059-1068","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis"],"prefix":"10.1182","volume":"123","author":[{"given":"S. Leah","family":"Etheridge","sequence":"first","affiliation":[{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Sangkhae","sequence":"additional","affiliation":[{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana M.","family":"Corbo","sequence":"additional","affiliation":[{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Roh","sequence":"additional","affiliation":[{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus A.","family":"Seeliger","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stony Brook University, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian S.","family":"Hitchcock","sequence":"additional","affiliation":[{"name":"Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7037","key":"2019111822015342500_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2019111822015342500_B2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111822015342500_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"2019111822015342500_B4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"2019111822015342500_B5","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111822015342500_B6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2353\/jmoldx.2006.050128","article-title":"Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.","volume":"8","author":"Horn","year":"2006","journal-title":"J Mol Diagn"},{"issue":"1","key":"2019111822015342500_B7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2353\/jmoldx.2009.080114","article-title":"Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.","volume":"11","author":"Ma","year":"2009","journal-title":"J Mol Diagn"},{"issue":"3","key":"2019111822015342500_B8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111822015342500_B9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111822015342500_B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PDM.0b013e3181ecd261","article-title":"MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.","volume":"20","author":"Ma","year":"2011","journal-title":"Diagn Mol Pathol"},{"issue":"7","key":"2019111822015342500_B11","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"4","key":"2019111822015342500_B12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000140630","article-title":"KIT and mastocytosis.","volume":"119","author":"Lim","year":"2008","journal-title":"Acta Haematol"},{"issue":"22","key":"2019111822015342500_B13","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111822015342500_B14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes.","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat Genet"},{"issue":"3","key":"2019111822015342500_B15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/ehm.10.28","article-title":"JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.","volume":"3","author":"Oh","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"2019111822015342500_B16","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"32","key":"2019111822015342500_B17","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1038\/onc.2011.68","article-title":"Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control.","volume":"30","author":"J\u00e4kel","year":"2011","journal-title":"Oncogene"},{"issue":"5","key":"2019111822015342500_B18","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2007-09-113860","article-title":"Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.","volume":"112","author":"Agarwal","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111822015342500_B19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bbrc.2009.04.015","article-title":"p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation.","volume":"383","author":"Furuhata","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"2019111822015342500_B20","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2006-08-039735","article-title":"The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.","volume":"109","author":"Hookham","year":"2007","journal-title":"Blood"},{"issue":"34","key":"2019111822015342500_B21","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1038\/onc.2009.155","article-title":"SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.","volume":"28","author":"Haan","year":"2009","journal-title":"Oncogene"},{"issue":"20","key":"2019111822015342500_B22","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood-2012-05-430926","article-title":"Impact of isolated germline JAK2V617I mutation on human hematopoiesis.","volume":"121","author":"Mead","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111822015342500_B23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2 mutation in a family with hereditary thrombocytosis.","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111822015342500_B24","author":"Pan"},{"issue":"5","key":"2019111822015342500_B25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2006-09-018655","article-title":"X-linked clonality testing: interpretation and limitations.","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111822015342500_B26","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2008-01-134049","article-title":"YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation.","volume":"112","author":"Hitchcock","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111822015342500_B27","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1128\/MCB.24.11.4955-4967.2004","article-title":"Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity.","volume":"24","author":"Argetsinger","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2019111822015342500_B28","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1128\/MCB.24.11.4968-4978.2004","article-title":"Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling.","volume":"24","author":"Feener","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"26","key":"2019111822015342500_B29","doi-asserted-by":"crossref","first-page":"18177","DOI":"10.1074\/jbc.M600064200","article-title":"Activated Jak2 with the V617F point mutation promotes G1\/S phase transition.","volume":"281","author":"Walz","year":"2006","journal-title":"J Biol Chem"},{"issue":"8","key":"2019111822015342500_B30","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111822015342500_B31","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"7414","key":"2019111822015342500_B32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"15","key":"2019111822015342500_B33","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"2019111822015342500_B34","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2009.1.636","article-title":"Therapeutic potential of JAK2 inhibitors.","author":"Verstovsek","year":"2009","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"39","key":"2019111822015342500_B35","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1074\/jbc.M109.011387","article-title":"A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation.","volume":"284","author":"Zhao","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111822015342500_B36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2009.007542","article-title":"Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis.","volume":"95","author":"Teofili","year":"2010","journal-title":"Haematologica"},{"key":"2019111822015342500_B37","author":"Cross"},{"issue":"10","key":"2019111822015342500_B38","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/7\/1059\/538062\/1059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/7\/1059\/538062\/1059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:02:20Z","timestamp":1574114540000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/7\/1059\/105686\/A-novel-activating-germline-JAK2-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,13]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-12-473777","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718225563.793493057","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,13]]}}}